Public Health England

Protecting and improving the nation's health

Wellington House
133-155 Waterloo Road
London SE1 8UG
Tel: 020 7654 8000
www.phe.gov.uk

Russell Hope
Head of Bacteraemia and CDI Surveillance Section

Public Health England
NIS
HCAI and AMR/Bacteraemia and CDI Surveillance Section
61 Colindale Ave
LONDON
NW9 5EQ

05 April 2018

Ref number **CGRP2017_17**

Dear Applicant

Re: Mandatory Surveillance of Healthcare Associated Bloodstream Infections and *Clostridium difficile* Infection. (PHE Caldicott Advisory Panel)

Thank you for your application, submitted for assessment under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002 to process patient identifiable information without consent.

The role of the PHE Caldicott Advisory Panel is to review applications submitted under these Regulations and to provide advice on whether an application should be supported and, if so, any relevant conditions. This application was considered at the Review Panel meeting held on **13 February 2018.**

The PHE Caldicott Advisory Panel

Supports the proposal subject to compliance with the standard and specific conditions

Under Regulation 7 of the Health Service (Control of Patient Information) Regulations 2002, the PHE Caldicott Guardian support is subject to submission of an annual review report showing that the application is still able to demonstrate the legal basis for processing Patient Confidential Data.

It is your responsibility to review data, report any changes (such as to the purpose or design of the proposed activity, or to security and confidentiality arrangements) and submit this report within 12 months from the Panel date.

An annual review should therefore be provided no later than **02 January 2019**.

If at any stage you no longer require support under the Regulations, please notify the Caldicott Office immediately.

Please do not hesitate to contact the Caldicott Office in the first instance if you need any further assistance (caldicott@phe.gov.uk).

Yours sincerely



Professor Anthony Kessel
PHE Caldicott Guardian

<table>
<tr><td>Proposal Title</td><td>Mandatory Surveillance of Healthcare Associated Bloodstream Infections and Clostridium difficile Infection</td></tr>
<tr><td>Caldicott Review Panel reference number</td><td>CGRP2017_17</td></tr>
<tr><td>Caldicott Review Panel Date</td><td>13 February 2018</td></tr>
<tr><td>Information Asset Number</td><td>37895</td></tr>
<tr><td>Information Asset Owner</td><td>Derrick Crook</td></tr>
<tr><td>Information System Owner</td><td>Russell Hope</td></tr>
<tr><td>Legal basis for processing</td><td>Regulation 3</td></tr>
<tr><td>Classification of Regulation 3 support
(if Regulation 3 support approved)</td><td>
<table>
<tr><td>b</td><td>Recognising trends in such diseases and risks</td></tr>
<tr><td>c</td><td>Controlling and preventing the spread of such diseases and risks</td></tr>
<tr><td>d(i)</td><td>Monitoring and managing outbreaks of communicable disease</td></tr>
<tr><td>d(ii)</td><td>Monitoring and managing incidents of exposure to communicable disease</td></tr>
</table>
</td></tr>
<tr><td>Opinion</td><td>Panel is in agreement that it is within the Regulation 3 and supports the proposal.</td></tr>
<tr><td>Rationale</td><td>Collection is mandated by NHS-Improvement (previously by the Department of Health) on behalf of the Health Secretary. Section 251 regulation 3 provides the legal cover not to seek individual patient consent. Note this cover is for all users and organisations contributing to this surveillance not just PHE.
The application is concerned with merely mandating two additional organisms to the surveillance and does not change the legal basis for processing</td></tr>
<tr><td>Recommendations
(conditions of approval)</td><td>-</td></tr>
<tr><td>Date</td><td>13 February 2018</td></tr>
<tr><td>Supported by</td><td>Professor Anthony Kessel
PHE Caldicott Guardian</td></tr>
<tr><td>Next review</td><td>13 February 2019</td></tr>
</table>